StimLabs, a leader in regenerative technologies and products that are revolutionizing patient care through innovation and personalized solutions, announced the launch of a new placental membrane-based product, Enverse.

StimLabs is expanding their product portfolio to address the widening range of needs in healthcare facilities. The introduction of Enverse is part of StimLabs' aim to simplify patient care for both physicians and the hospital systems in which they practice. Both physician owned and hospital owned facilities now have StimLabs' solutions at their disposal.

Enverse is a translucent dehydrated complete human placental membrane (dCHPM) allograft designed for use as a wound covering over acute and chronic wounds. The dCHPM allograft is processed to retain the intermediate layer using the patented Clearify method.

StimLabs' differentiated placental membrane-based product portfolio remains of the highest quality with each product processed using StimLabs' patented Clearify process.